Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, reflects on the expanding treatment landscape of HER2-positive breast cancer which brings forward the question of how to best sequence HER2-targeting agents, including novel agents such as trastuzumab deruxtecan (T-DXd), tucatinib, and trastuzumab emtansine (T-DM1) in later lines of treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть